3-([(Tert-butoxy)carbonyl]amino)hex-5-ynoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-([(Tert-butoxy)carbonyl]amino)hex-5-ynoic acid
• 英文别名: 3-[(2-methylpropan-2-yl)oxycarbonylamino]hex-5-ynoic acid
• 化学式: C₁₁H₁₇NO₄
• 分子量: 227.26
• InChiKey: QZRLAJLEZVWLOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY
  申请人：Sixfold Bioscience Ltd.

  公开号：US20210330810A1

  公开（公告）日：2021-10-28

  The invention provides compositions containing cargo molecules attached to elements that improve the function of the cargo molecules in the body of a subject. The compositions are useful for therapeutic and diagnostic purposes. Furthermore, the invention outlines ways in which these compositions can be produced; the core molecule can be functionalized, via bioorthogonal click chemistry, in such a way as to impart modular characteristics. This functionalization simultaneously allows for loading of biologically relevant cargo and provides stabilization to the overall structure of the molecule.

  本发明提供了一种包含附着于能够改善受试者体内载荷分子功能的元素的组合物。该组合物在治疗和诊断方面具有用途。此外，本发明还概述了可生产这些组合物的方法；核心分子可以通过生物正交点击化学功能化，以赋予模块化特性。这种功能化同时允许装载生物相关载荷并为分子的整体结构提供稳定性。
• Complement Pathway Modulators and Uses Thereof
  申请人：NOVARTIS AG

  公开号：US20150126492A1

  公开（公告）日：2015-05-07

  The present invention provides a compound of formula I a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitor of the complement alternative pathway and particularly as inhibitor of Factor B for the treatment of e.g. age-related macular degeneration and diabetic retinopathy. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种I式化合物，一种制造该化合物的方法，以及其作为补体替代途径抑制剂的治疗用途，特别是作为抑制因子B的治疗用途，例如治疗与年龄相关的黄斑部病变和糖尿病视网膜病变。本发明还提供了药理活性剂的组合和制药组合物。
• PHARMACEUTICAL COMPOSITIONS COMPRISING RILUZOLE PRODRUGS
  申请人：Biohaven Pharmaceutical Holding Company Ltd.

  公开号：EP4011870A1

  公开（公告）日：2022-06-15

  Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

  本发明的药物组合物包括取代的利鲁唑原药，可通过释放利鲁唑治疗癌症，包括黑色素瘤、乳腺癌、脑癌和前列腺癌。利鲁唑原药对肝脏代谢的稳定性增强，通过口服进入全身循环，然后通过酶或一般生物物理释放过程裂解，在血浆中释放利鲁唑。
• Prodrugs of riluzole and their method of use
  申请人：Biohaven Pharmaceutical Holding Company Ltd.

  公开号：US10639298B2

  公开（公告）日：2020-05-05

  Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

  本发明的药物组合物包括取代的利鲁唑原药，可通过释放利鲁唑治疗癌症，包括黑色素瘤、乳腺癌、脑癌和前列腺癌。利鲁唑原药对肝脏代谢的稳定性增强，通过口服进入全身循环，然后通过酶或一般生物物理释放过程裂解，在血浆中释放利鲁唑。
• Riluzole prodrugs and their use
  申请人：Biohaven Therapeutics Ltd.

  公开号：US10905681B2

  公开（公告）日：2021-02-02

  Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

  本发明的药物组合物包括取代的利鲁唑原药，可通过释放利鲁唑治疗癌症，包括黑色素瘤、乳腺癌、脑癌和前列腺癌。利鲁唑原药对肝脏代谢的稳定性增强，通过口服进入全身循环，然后通过酶或一般生物物理释放过程裂解，在血浆中释放利鲁唑。